Posted by Michael Wonder on 14 Mar 2018
NovaBiotics’ Lynovex receives fast track designation for cystic fibrosis exacerbations
12 March 2018 - NovaBiotics announces receipt of fast track designation for its cystic fibrosis therapy, Lynovex, from the United States FDA.
Lynovex is a novel, highly differentiated therapy for the treatment of cystic fibrosis (CF)-associated lung disease, with a unique dual mode of action. Lynovex breaks down the thick, sticky mucus produced by the lining of the airways in CF patients, and kills the bacteria that thrive in this environment and occasionally “flare” as serious chest infections (exacerbations).
Lynovex also boosts the activity of standard-of-care CF antibiotics and is intended for use alongside these and other existing CF therapies as well as the more recently approved ‘disease modifiers’ that can work in certain patients to correct or potentiate the faulty CFTR protein that causes the disease. Importantly, Lynovex is a therapy designed to treat all CF patients and is not specific to patients with specific mutations/disease genotypes.
